Predicting Drug-Disease Associations via Using Gaussian Interaction Profile and Kernel-Based Autoencoder

• Published in: BioMed research international Vol. 2019; no. 2019; pp. 1 - 11
• Main Authors: Jiang, Han-Jing, You, Zhu-Hong, Huang, Yu-An
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 2019; Hindawi; John Wiley & Sons, Inc
• Subjects: Algorithms; Alzheimer Disease - drug therapy; Alzheimer's disease; Analysis; Annual reports; Artificial intelligence; Bioinformatics; Case studies; Classification; Complexity; Computational Biology; Computer applications; Computer Simulation; Databases, Factual; Deep learning; Disease; Drug development; Drug interactions; Drug Repositioning; Drugs; Humans; Kernels; Learning algorithms; Machine Learning; Mathematical models; Medical research; Medicine, Experimental; Methods; Model accuracy; Neurodegenerative diseases; Predictions; Proteins; Recommender systems; Respiratory agents; Semantics
• ISSN: 2314-6133; 2314-6141; 2314-6141
• DOI: 10.1155/2019/2426958

Computational drug repositioning, designed to identify new indications for existing drugs, significantly reduced the cost and time involved in drug development. Prediction of drug-disease associations is promising for drug repositioning. Recent years have witnessed an increasing number of machine learning-based methods for calculating drug repositioning. In this paper, a novel feature learning method based on Gaussian interaction profile kernel and autoencoder (GIPAE) is proposed for drug-disease association. In order to further reduce the computation cost, both batch normalization layer and the full-connected layer are introduced to reduce training complexity. The experimental results of 10-fold cross validation indicate that the proposed method achieves superior performance on Fdataset and Cdataset with the AUCs of 93.30% and 96.03%, respectively, which were higher than many previous computational models. To further assess the accuracy of GIPAE, we conducted case studies on two complex human diseases. The top 20 drugs predicted, 14 obesity-related drugs, and 11 drugs related to Alzheimer's disease were validated in the CTD database. The results of cross validation and case studies indicated that GIPAE is a reliable model for predicting drug-disease associations.